

+

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(use as many sheets as necessary)

Application Number	Unassigned
Filing Date	December 3, 2003
First Named Inventor	Jeffrey SCHLOM et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	38163-0197

[illegible][illegible]

Marlene D

5 | 23 | 05

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	Unassigned
Filing Date	December 3, 2003
First Named Inventor	Jeffrey SCHLOM et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	38163-0197

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MD	A04	Tsang, K.Y., et al., Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst., 87:982-990 (1995).	
MD	A05	Jameson, S.C., et al., T cell receptor antagonists and partial agonists. Immunity, 2:1-11 (1995).	
MD	A06	Chen, Y., et al., Response of a human T cell clone to a large panel of altered peptide ligands carrying single residue substitutions in an antigenic peptide: characterization and frequencies of TCR agonist and TCR antagonism with or without partial activation. J. Immunol., 157: 3783-3790 (1996).	
MD	A07	Tsang, K.Y., et al., J. Phenotypic Stability of a Cytotoxic T Cell Line Directed Against an Immunodominant Epitope of Human Carcinoembryonic Antigen. Clinical Cancer Res., 12:2349 (1997).	
MD	A08	Zaremba, S. et al. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Research. 57:4570-4577 (1997).	
MD	A09	Ras, E. et al. "Identification of Potential HLA-A*0201 Restricted CTL Epitopes Derived from the Epithelial Cell Adhesion Molecule and the Carcinoembryonic Antigen (CEA)" Hum. Imm. 53:81-89 (1997).	
MD	A10	Madden et al. "The Antigenic Identity of Peptide-MHC Complexes: A Comparison of the Conformation of Five Viral Peptides presented by HLA-A2" Cell 75:693-708 (1993).	
MD	A11	Skipper et al., "An HLA-A2-restricted Tyrosinase Antigen on Melanoma Cells from Post-translational Modification and Suggests a Novel Pathway for Processing of Membrane Protein", J. Exp. Med. 1996 <i>Volume 183</i>	
MD	A12	NCBI Blast search Accession P06731, 1987	

Examiner
Signature*Manane D*Date
Considered

5/23/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.